The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Lung most cancers analysis and affected person experiences made headlines in 2025, from surgical advances and focused therapies to private tales that...
Dr. Vinayak Venkataraman sat down for an interview with CURE to debate the evolving remedy panorama for gastrointestinal stromal tumors (GIST), with...
Revolution Medicines introduced in a information launch that the U.S. Meals and Drug Administration (FDA) granted breakthrough remedy designation to zoldonrasib for...
